Incyte Corporation INCY
Healthcare · Biotechnology · United States · S&P 500
Based on the available data, Incyte Corporation gets an algorithmic score of 96/100. It trades at 123.20 $, with a bullish technical trend (RSI 47.4) and 33.1% annual volatility.
Updated: 2026-09-30
Open in the interactive tool →
Strengths
- High ROE (30.7%): generates strong profit on equity.
- High net margin (27.7%): pricing power / competitive advantage.
- Sustained revenue growth (14.8% compound annual).
- Low-debt balance sheet.
- Attractive free-cash-flow yield (5.3%).
- Low beta (0.51): defensive profile.
Weaknesses
- —
Fundamentals
| P/E | 15.69 |
| Forward P/E | 13.92 |
| PEG | 10.82 |
| P/B | 3.90 |
| EV/EBITDA | 10.54 |
| P/S | 4.29 |
| ROE % | 30.67 |
| ROA % | 16.83 |
| Gross margin % | 55.66 |
| Operating margin % | 41.90 |
| Net margin % | 27.71 |
| Revenue growth % (y/y) | 37.70 |
| Earnings growth % (y/y) | 37.70 |
| Revenue CAGR % | 14.84 |
| Earnings CAGR % | 55.73 |
| Debt/Equity % | 0.60 |
| Current ratio | 4.59 |
| FCF yield % | 5.32 |
| Dividend yield % | 0.00 |
| Payout % | 0.00 |
Returns
| 1 month | -0.9 % |
| 3 months | +8.7 % |
| 6 months | +36.4 % |
| YTD | +21.5 % |
| 1 year | +49.0 % |
| 3 years | +112.0 % |
| 5 years | +62.0 % |
Risk
| 1-year volatility | 33.1 % |
| Beta | 0.51 |
| 5-year max drawdown | -40.5 % |
| Sharpe 1A | 1.25 |
Macroeconomic context
Defensive with structural growth (ageing population). Risks: drug-pricing regulation, patents and clinical trials. Low correlation with the cycle. As a US company, its valuation depends on the Fed, 10-year Treasury yields and the US earnings cycle.
How the score is calculated
The score combines profitability (ROE, ROA, net margin), growth (revenue and earnings), valuation (P/E, EV/EBITDA, free cash flow), financial strength (debt and liquidity; not applied to banks and insurers) and momentum (6 and 12-month returns and trend). It is an educational quantitative filter, not a buy or sell recommendation.